Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
---|---|---|---|---|---|
Total Cash And Short-Term Investments | 176.50M | 234.40M | 309.81M | 373.29M | 371.36M |
Total Receivables | 547.00K | 1.73M | 4.19M | 20.65M | 40.55M |
Inventory | -- | -- | -- | -- | 38.32M |
Prepaid Expenses | 12.38M | 9.14M | 12.72M | 16.59M | 14.43M |
Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
Other Current Assets | -- | -- | -- | -- | -- |
Total Current Assets | 189.43M | 245.26M | 326.72M | 410.53M | 464.67M |
|
|||||
Total Current Assets | 189.43M | 245.26M | 326.72M | 410.53M | 464.67M |
Net Property, Plant & Equipment | 2.73M | 3.53M | 4.24M | 5.71M | 6.41M |
Long-term Investments | -- | -- | -- | -- | -- |
Goodwill | -- | -- | -- | -- | -- |
Total Other Intangibles | -- | -- | -- | -- | -- |
Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
Total Other Assets | 1.47M | 1.92M | 1.20M | 1.21M | 46.38M |
Total Assets | 193.63M | 250.71M | 332.16M | 417.46M | 517.45M |
|
|||||
Total Accounts Payable | 2.94M | 1.49M | 4.96M | 21.45M | 22.06M |
Total Accrued Expenses | 23.95M | 50.46M | 62.76M | 67.87M | 57.72M |
Short-term Debt | -- | -- | -- | -- | -- |
Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
Finance Division Debt Current | 1.52M | 1.97M | 2.37M | 2.31M | 2.26M |
Total Finance Division Other Current Liabilities | -- | -- | -- | -- | -- |
Total Other Current Liabilities | -- | -- | -- | -- | -- |
Total Current Liabilities | 28.41M | 53.92M | 70.08M | 91.64M | 82.04M |
|
|||||
Total Current Liabilities | 28.41M | 53.92M | 70.08M | 91.64M | 82.04M |
Long-Term Debt | -- | -- | -- | -- | -- |
Short-term Debt | -- | -- | -- | -- | -- |
Capital Leases | 463.00K | 595.00K | 772.00K | 1.38M | 1.98M |
Finance Division Debt Non Current | -- | -- | -- | -- | -- |
Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
Total Other Liabilities | -- | -- | -- | -- | -- |
Total Liabilities | 28.87M | 54.51M | 70.85M | 93.02M | 84.02M |
|
|||||
Common Stock & APIC | 771.55M | 764.71M | 757.85M | 748.26M | 738.18M |
Retained Earnings | -606.69M | -569.15M | -496.44M | -423.74M | -304.95M |
Treasury Stock & Other | -92.00K | 641.00K | -97.00K | -77.00K | 197.00K |
Total Common Equity | 164.77M | 196.20M | 261.31M | 324.44M | 433.43M |
|
|||||
Preferred Stock Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
Preferred Stock Convertible | -- | -- | -- | -- | -- |
Preferred Stock, Others | -- | -- | -- | -- | -- |
Total Preferred Equity | -- | -- | -- | -- | -- |
|
|||||
Total Common Equity | 164.77M | 196.20M | 261.31M | 324.44M | 433.43M |
Total Preferred Equity | -- | -- | -- | -- | -- |
Total Minority Interest | -- | -- | -- | -- | -- |
Total Equity | 164.77M | 196.20M | 261.31M | 324.44M | 433.43M |
|